Percutaneous Coronary Intervention using a Full Metal Jacket with Drug-eluting Stents: Major Adverse Cardiac Events at One Year

Methods: We enrolled 136 consecutive patients with long coronary lesions requiring FMJ in our single-center registry. The primary endpoint included the combined occurrence of all-cause death, myocardial infarction (MI), and target vessel revascularization (TVR). Demographic, clinical, angiographic, and procedural variables were evaluated using stepwise Cox regression analysis to determine independent predictors of outcome.

[1]  Jeroen J. Bax,et al.  The universal definition of myocardial infarction , 2015, Oxford Medicine Online.

[2]  Seung‐Jung Park,et al.  Comparison of Resolute Zotarolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients With De Novo Long Coronary Artery Lesions: A Randomized LONG-DES IV Trial , 2012, Circulation. Cardiovascular Interventions.

[3]  I. Seong,et al.  Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. , 2011, JACC. Cardiovascular interventions.

[4]  J. López-Sendón,et al.  Safety and efficacy of drug-eluting stents versus bare-metal stents in saphenous vein grafts lesions: a meta-analysis. , 2010 .

[5]  Peter L Duffy,et al.  Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group. , 2009, JACC. Cardiovascular interventions.

[6]  A. Colombo,et al.  Long-Term Follow-Up on a Large Cohort of “Full-Metal Jacket” Percutaneous Coronary Intervention Procedures , 2009, Circulation. Cardiovascular interventions.

[7]  Peter Jüni,et al.  Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent Thrombosis , 2009, Circulation.

[8]  D. Ramsdale,et al.  Clinical outcomes after percutaneous coronary intervention involving very long segments of drug-eluting stent implantation: single-center experience. , 2009, The Journal of invasive cardiology.

[9]  Katja Zeppenfeld,et al.  Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: acute and 9-month intravascular ultrasound results of the MISSION! intervention study. , 2008, JACC. Cardiovascular interventions.

[10]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[11]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[12]  J. Popma,et al.  Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial: Support for the Use of Drug-Eluting Stents in Contemporary Clinical Practice , 2005, Circulation.

[13]  P. Serruys,et al.  "Full metal jacket" (stented length > or =64 mm) using drug-eluting stents for de novo coronary artery lesions. , 2005, American heart journal.

[14]  Gregg W Stone,et al.  Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. , 2005, JAMA.

[15]  I. Iakovou,et al.  Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. , 2005, Journal of the American College of Cardiology.

[16]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[17]  Fernando Alfonso,et al.  Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. , 2005, Journal of the American College of Cardiology.

[18]  A. Kastrati,et al.  Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. , 2002, Journal of the American College of Cardiology.

[19]  P. Serruys,et al.  A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions: final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study. , 2002, Journal of the American College of Cardiology.

[20]  P. Serruys,et al.  The influence of stent length on clinical and angiographic outcome in patients undergoing elective stenting for native coronary artery lesions; final results of the Magic 5L Study. , 2001, European heart journal.

[21]  G. Mintz,et al.  Coronary in-stent restenosis - predictors, treatment and prevention. , 2000, European heart journal.

[22]  C. Di Mario,et al.  Stented segment length as an independent predictor of restenosis. , 1999, Journal of the American College of Cardiology.

[23]  M. Hadamitzky,et al.  Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. , 1998, Journal of the American College of Cardiology.

[24]  M. Hadamitzky,et al.  Intracoronary stenting and risk for major adverse cardiac events during the first month. , 1998, Circulation.

[25]  R Waksman,et al.  Procedural results and late clinical outcomes after placement of three or more stents in single coronary lesions. , 1998, Circulation.

[26]  M. Hadamitzky,et al.  Predictive factors of restenosis after coronary stent placement. , 1997, Journal of the American College of Cardiology.

[27]  E. Topol,et al.  Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. , 1993, Journal of the American College of Cardiology.

[28]  Seung‐Jung Park,et al.  Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions. , 2006, The American journal of cardiology.

[29]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .